(Patient-derived) organoids and xenografts for oncology.

Cancer is one of the leading causes of death in industrialized countries. Major breakthroughs in drug discovery for oncology have been hampered by the high costs and the high attrition rate. Classical human cancer models used are cancer cell lines (2D) and in-vivo animal models. Although these oncology models have proven to be useful in the past their utility towards the clinic has vast room for improvement.

InnoSer has started exploring the field of tissue-derived organoids that are obtained during surgery or biopsy comprising of human tumor tissue that are termed Patient Derived Organoid (PDO). Also, a combined model of an organoid and a mouse xenograft that is thoroughly characterized in the same manner (PDXO) provides a closer to clinic double model (in-vitro and in-vivo) of the same parental tumor.

Recently InnoSer has teamed up with leading edge research groups from both academia and industrial partners which has led to a collaborative project to establish esophageal, gastric, lung, pancreas, liver and B cell lymphoma PDXO models.

InnoSer is validating the PDXO model to develop a fast and reliable screening platform in the drug discovery and preclinical drug development chain.

MD, PhD Marije Slingerland

Involved in InnoSer’s Scientific Advisory Board, Dr. Slingerland from Leiden University Medical Center focuses on clinical trials in gastrointestinal cancer and in head and neck cancer, particularly on intratumoral immune parameters.

Interested In InnoSer’s Oncology Services?

Get in touch with us.